Abstract is: Wendy Sue Fox CBE FMedSci (née Barclay) is a British virologist. She is currently head of Department of Infectious Disease and Chair in Influenza Virology at Imperial College London. She leads a team of scientists studying the influenza virus and its physiology and morphology to discover novel vaccines. In particular, they are trying to understand more about influenza virus mutations, and how they can allow scientists to create new vaccines against possible flu pandemics.
| human | Q5 |
| P646 | Freebase ID | /m/0138n3k7 |
| P269 | IdRef ID | 252350162 |
| P345 | IMDb ID | nm3857949 |
| P213 | ISNI | 000000012441234X |
| P856 | official website | https://www.imperial.ac.uk/people/w.barclay |
| P496 | ORCID iD | 0000-0002-3948-0895 |
| P1153 | Scopus author ID | 7005440974 |
| P214 | VIAF ID | 272161272151747441236 |
| P2002 | X username | wendybarclay11 |
| P1416 | affiliation | Imperial College London | Q189022 |
| P6424 | affiliation string | Imperial College London | |
| P166 | award received | Commander of the Order of the British Empire | Q12201477 |
| P69 | educated at | University of Reading | Q1432632 |
| Blackheath High School | Q4922996 | ||
| P108 | employer | Imperial College London | Q189022 |
| P734 | family name | Barclay | Q16243195 |
| Barclay | Q16243195 | ||
| Barclay | Q16243195 | ||
| P101 | field of work | virology | Q7215 |
| P735 | given name | Wendy | Q4018995 |
| Wendy | Q4018995 | ||
| P737 | influenced by | Peter Palese | Q1795041 |
| P463 | member of | Scientific Advisory Group for Emergencies | Q88096332 |
| New and Emerging Respiratory Virus Threats Advisory Group | Q88099150 | ||
| P106 | occupation | virologist | Q15634281 |
| P1344 | participant in | World Economic Forum Annual Meeting 2019 | Q114717235 |
| P21 | sex or gender | female | Q6581072 |
| Q112710104 | A common TMPRSS2 variant has a protective effect against severe COVID-19 |
| Q37275127 | A complicated message: Identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA. |
| Q40532455 | A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria |
| Q30228084 | A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine |
| Q39685928 | A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA. |
| Q30408155 | A single amino acid in the HA of pH1N1 2009 influenza virus affects cell tropism in human airway epithelium, but not transmission in ferrets |
| Q96291833 | ACE2: The Only Thing That Matters? |
| Q92883453 | ANP32 Proteins Are Essential for Influenza Virus Replication in Human Cells |
| Q30366662 | Accumulation of human-adapting mutations during circulation of A(H1N1)pdm09 influenza virus in humans in the United Kingdom. |
| Q39614628 | Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines |
| Q40099360 | Alterations in receptor binding properties of recent human influenza H3N2 viruses are associated with reduced natural killer cell lysis of infected cells. |
| Q38865842 | Amino acid substitution D222N from fatal influenza infection affects receptor-binding properties of the influenza A(H1N1)pdm09 virus |
| Q38758122 | An engineered avian-origin influenza A virus for pancreatic ductal adenocarcinoma virotherapy |
| Q30412888 | An influenza reassortant with polymerase of pH1N1 and NS gene of H3N2 influenza A virus is attenuated in vivo |
| Q108819011 | Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults |
| Q36438526 | Antigenic mapping of an H9N2 avian influenza virus reveals two discrete antigenic sites and a novel mechanism of immune escape |
| Q39227786 | Antiviral Screening of Multiple Compounds against Ebola Virus |
| Q35605579 | Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry |
| Q59353775 | Assays to Measure the Activity of Influenza Virus Polymerase |
| Q99610109 | Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study |
| Q63408422 | Attenuating mutations in the influenza virus genome which may increase the safety of vaccine production |
| Q61228840 | Avian ANP32B does not support influenza A virus polymerase and influenza A virus relies exclusively on ANP32A in chicken cells.: Supplementary Information |
| Q33444633 | Avian Influenza virus glycoproteins restrict virus replication and spread through human airway epithelium at temperatures of the proximal airways |
| Q91955949 | Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission |
| Q47573057 | Can defective interfering RNAs affect the live attenuated influenza vaccine? - Authors' reply |
| Q30353819 | Cellular immune correlates of protection against symptomatic pandemic influenza. |
| Q40577158 | Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host |
| Q89876357 | Characterising viable virus from air exhaled by H1N1 influenza-infected ferrets reveals the importance of haemagglutinin stability for airborne infectivity |
| Q40467433 | Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. |
| Q98470301 | Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey |
| Q37238003 | Computational and molecular analysis of conserved influenza A virus RNA secondary structures involved in infectious virion production |
| Q28384431 | Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance |
| Q58089569 | Determining the Mutation Bias of Favipiravir in Influenza Using Next-generation Sequencing |
| Q62898069 | Determining the Mutation Bias of Favipiravir in Influenza Using Next-generation Sequencing |
| Q40134334 | Development of a reverse genetics system enabling the rescue of recombinant avian influenza virus A/Turkey/England/50-92/91 (H5N1). |
| Q92997467 | Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study |
| Q91151083 | Elucidating the Interactions between Influenza Virus Polymerase and Host Factor ANP32A |
| Q92267294 | Entry of the bat influenza H17N10 virus into mammalian cells is enabled by the MHC class II HLA-DR receptor |
| Q112722302 | Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model |
| Q39680151 | Evidence for avian and human host cell factors that affect the activity of influenza virus polymerase |
| Q33513974 | Fatal cases of influenza a in childhood |
| Q41249449 | Ferret airway epithelial cell cultures support efficient replication of influenza B virus but not mumps virus |
| Q55399537 | Ferrets as Models for Influenza Virus Transmission Studies and Pandemic Risk Assessments. |
| Q30376964 | Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat |
| Q125880271 | Genomic screening of 16 UK native bat species through conservationist networks uncovers coronaviruses with zoonotic potential |
| Q34317413 | Glycomic characterization of respiratory tract tissues of ferrets: implications for its use in influenza virus infection studies |
| Q33865132 | HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation |
| Q108819005 | High and increasing prevalence of SARS-CoV-2 swab positivity in England during end September beginning October 2020: REACT-1 round 5 updated report |
| Q104659121 | High prevalence of SARS-CoV-2 swab positivity and increasing R number in England during October 2020: REACT-1 round 6 interim report |
| Q108819007 | High prevalence of SARS-CoV-2 swab positivity in England during September 2020: interim report of round 5 of REACT-1 study |
| Q102152437 | Host ANP32A mediates the assembly of the influenza virus replicase |
| Q100315715 | Host Cell Factors That Interact with Influenza Virus Ribonucleoproteins |
| Q91707062 | Host Determinants of Influenza RNA Synthesis |
| Q59349660 | Host and viral determinants of influenza A virus species specificity |
| Q24336824 | Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection |
| Q59569190 | Identification of novel expressed sequences, up-regulated in the leucocytes of chronic fatigue syndrome patients |
| Q30401640 | Immune Escape Variants of H9N2 Influenza Viruses Containing Deletions at the Hemagglutinin Receptor Binding Site Retain Fitness In Vivo and Display Enhanced Zoonotic Characteristics |
| Q34199805 | Immune responses in pigs vaccinated with adjuvanted and non-adjuvanted A(H1N1)pdm/09 influenza vaccines used in human immunization programmes |
| Q108818986 | Increasing SARS-CoV-2 antibody prevalence in England at the start of the second wave: REACT-2 Round 4 cross-sectional study in 160,000 adults |
| Q30355972 | Infection of human airway epithelium by human and avian strains of influenza a virus. |
| Q39044498 | Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). |
| Q38325400 | Influence of PB2 host-range determinants on the intranuclear mobility of the influenza A virus polymerase |
| Q40563817 | Influenza A virus PB1-F2 protein prolongs viral shedding in chickens lengthening the transmission window |
| Q92689668 | Influenza Virus with Increased pH of Hemagglutinin Activation Has Improved Replication in Cell Culture but at the Cost of Infectivity in Human Airway Epithelium |
| Q37962433 | Influenza pandemics |
| Q38768547 | Influenza: a world of discoveries, outbreaks and controversy |
| Q47210087 | Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. |
| Q36506769 | Investigation of influenza virus polymerase activity in pig cells |
| Q38673915 | Knowns and unknowns of influenza B viruses |
| Q39555531 | Lack of transmission of a human influenza virus with avian receptor specificity between ferrets is not due to decreased virus shedding but rather a lower infectivity in vivo |
| Q30361125 | Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir. |
| Q37730817 | M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza |
| Q45421935 | Molecular characterization of Iranian wheat stripe virus shows its taxonomic position as a distinct species in the genus Tenuivirus. |
| Q37798373 | Molecular studies of influenza B virus in the reverse genetics era. |
| Q49409333 | Mouse Models of Influenza Infection with Circulating Strains to Test Seasonal Vaccine Efficacy |
| Q30382671 | Mutations in H5N1 influenza virus hemagglutinin that confer binding to human tracheal airway epithelium. |
| Q28385604 | Mutations in haemagglutinin that affect receptor binding and pH stability increase replication of a PR8 influenza virus with H5 HA in the upper respiratory tract of ferrets and may contribute to transmissibility |
| Q112709659 | Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway |
| Q37738395 | NB protein does not affect influenza B virus replication in vitro and is not required for replication in or transmission between ferrets |
| Q35784659 | NS1 proteins of avian influenza A viruses can act as antagonists of the human alpha/beta interferon response. |
| Q30427526 | Obesity and susceptibility to severe outcomes following respiratory viral infection |
| Q30370246 | One-way trip: influenza virus' adaptation to gallinaceous poultry may limit its pandemic potential. |
| Q116680016 | P251 The induction of early, dynamic airway mucosal and systemic immune responses following recent SARS-CoV-2 household exposure |
| Q30397718 | Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness |
| Q43138072 | Pandemic risks from bird flu. |
| Q91186385 | Passage of influenza A/H3N2 viruses in human airway cells removes artefactual variants associated with neuraminidase-mediated binding |
| Q37265666 | Pause on avian flu transmission research |
| Q30418993 | Predominance of heterosubtypic IFN-γ-only-secreting effector memory T cells in pandemic H1N1 naive adults |
| Q93013404 | Pregnancy-related immune suppression leads to altered influenza vaccine recall responses |
| Q104668085 | Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. |
| Q38302467 | Probing the receptor interactions of an H5 avian influenza virus using a baculovirus expression system and functionalised poly(acrylic acid) ligands |
| Q90605918 | Publisher Correction: Host and viral determinants of influenza A virus species specificity |
| Q100955033 | Quantifying mechanistic traits of influenza viral dynamics using in vitro data |
| Q108818991 | REACT-1 round 10 report: Level prevalence of SARS-CoV-2 swab-positivity in England during third national lockdown in March 2021 |
| Q108818988 | REACT-1 round 13 interim report: acceleration of SARS-CoV-2 Delta epidemic in the community in England during late June and early July 2021 |
| Q108819001 | REACT-1 round 6 updated report: high prevalence of SARS-CoV-2 swab positivity with reduced rate of growth in England at the start of November 2020 |
| Q108819000 | REACT-1 round 7 interim report: fall in prevalence of swab-positivity in England during national lockdown |
| Q108818998 | REACT-1 round 7 updated report: regional heterogeneity in changes in prevalence of SARS-CoV-2 infection during the second national COVID-19 lockdown in England |
| Q108818996 | REACT-1 round 8 final report: high average prevalence with regional heterogeneity of trends in SARS-CoV-2 infection in the community in England during January 2021 |
| Q108818997 | REACT-1 round 8 interim report: SARS-CoV-2 prevalence during the initial stages of the third national lockdown in England |
| Q108818993 | REACT-1 round 9 final report: Continued but slowing decline of prevalence of SARS-CoV-2 during national lockdown in England in February 2021 |
| Q108818995 | REACT-1 round 9 interim report: downward trend of SARS-CoV-2 in England in February 2021 but still at high prevalence |
| Q34097840 | RIG-I detects viral genomic RNA during negative-strand RNA virus infection |
| Q64082340 | RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals |
| Q39734394 | Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. |
| Q30396667 | Receptor binding profiles of avian influenza virus hemagglutinin subtypes on human cells as a predictor of pandemic potential |
| Q92063002 | Receptor for bat influenza virus uncovers potential risk to humans |
| Q40562546 | Reduced incorporation of the influenza B virus BM2 protein in virus particles decreases infectivity |
| Q92604841 | Regulation of influenza A virus mRNA splicing by CLK1 |
| Q40377049 | Restrictions to the adaptation of influenza a virus h5 hemagglutinin to the human host. |
| Q108819008 | Resurgence of SARS-CoV-2 in England: detection by community antigen surveillance |
| Q108818989 | Resurgence of SARS-CoV-2: Detection by community viral surveillance |
| Q107473201 | SARS-CoV-2 one year on: evidence for ongoing viral adaptation |
| Q126871061 | Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults |
| Q98384023 | Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza |
| Q36456422 | Species difference in ANP32A underlies influenza A virus polymerase host restriction |
| Q83232819 | Species specific differences in use of ANP32 proteins by influenza A virus |
| Q27650988 | Structure of an avian influenza A virus NS1 protein effector domain |
| Q30376923 | Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. |
| Q91738175 | Swine ANP32A supports avian influenza virus polymerase |
| Q57094088 | The 1918 Influenza Pandemic: one hundred years of progress, but where now? |
| Q98664923 | The Emergence of H7N7 Highly Pathogenic Avian Influenza Virus from Low Pathogenicity Avian Influenza Virus Using an in ovo Embryo Culture Model |
| Q35773994 | The Functional Study of the N-Terminal Region of Influenza B Virus Nucleoprotein |
| Q61229032 | The MHC class-II HLA-DR receptor mediates bat influenza A-like H17N10 virus entry into mammalian cells |
| Q108177412 | The Origins of SARS-CoV-2: A Critical Review |
| Q110461150 | The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry |
| Q91177233 | The cellular localization of avian influenza virus PB1-F2 protein alters the magnitude of IFN2 promoter and NFκB-dependent promoter antagonism in chicken cells |
| Q95260554 | The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection |
| Q37123100 | The effect of the PB2 mutation 627K on highly pathogenic H5N1 avian influenza virus is dependent on the virus lineage. |
| Q107473210 | The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets |
| Q57799444 | The mechanism of resistance to favipiravir in influenza |
| Q28390168 | The short stalk length of highly pathogenic avian influenza H5N1 virus neuraminidase limits transmission of pandemic H1N1 virus in ferrets |
| Q34059183 | Transfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor |
| Q108819017 | Transient dynamics of SARS-CoV-2 as England exited national lockdown |
| Q21134081 | Transmission of a 2009 H1N1 pandemic influenza virus occurs before fever is detected, in the ferret model |
| Q37338331 | Transmission studies resume for avian flu. |
| Q113269688 | Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England |
| Q99370208 | Ultrastructure of Cell Trafficking Pathways and Coronavirus: How to Recognise the Wolf Amongst the Sheep |
| Q63408423 | Unravelling the mysteries of influenza |
| Q39250932 | Unstable polymerase-nucleoprotein interaction is not responsible for avian influenza virus polymerase restriction in human cells |
| Q40093500 | Urgent challenges in implementing live attenuated influenza vaccine |
| Q98390814 | Usability and acceptability of home-based self-testing for SARS-CoV-2 antibodies for population surveillance |
| Q108818987 | Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study |
| Q30400181 | Variability in H9N2 haemagglutinin receptor-binding preference and the pH of fusion |
| Q40336119 | Variation in the ability of human influenza A viruses to induce and inhibit the IFN-beta pathway. |
| Q38192476 | Viral determinants of influenza A virus host range |
| Q30275435 | Viral factors in influenza pandemic risk assessment. |
| Wendy Barclay | wikipedia |
Search more.